Literature DB >> 30933417

Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia.

Kasper Adelborg1,2, Nickolaj R Kristensen1, Mette Nørgaard1, Shahram Bahmanyar3, Waleed Ghanima4, Karynsa Kilpatrick5, Henrik Frederiksen1,6, Charlotta Ekstrand3, Henrik T Sørensen1, Christian Fynbo Christiansen1.   

Abstract

Essentials Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count. We conducted a cohort study of 3 584 chronic ITP patients from the Nordic countries. Cardiovascular events occurred across all platelet count levels. Cardiovascular or bleeding events were strong prognostic factors for all-cause mortality. Background Among patients with chronic immune thrombocytopenia (cITP), little is known regarding risk factors for cardiovascular and bleeding outcomes and how these events influence mortality. Objectives We examined the rate of cardiovascular events and bleeding requiring a hospital contact according to platelet count levels, as well as the prognostic impact of these events on all-cause mortality in adult patients with cITP. Methods We identified all cITP patients registered in the Nordic Country Patient Registry for Romiplostim during 1996 to 2015. Absolute risks and hazard ratios across platelet count levels based on Cox regression analysis were computed, adjusting for age, sex, prevalent/incident cITP, smoking, and comorbidities. We also compared all-cause mortality rates in cITP patients with and without cardiovascular and bleeding events. Results Among 3 584 cITP patients, 1-year risks were 1.9% for arterial cardiovascular events, 1.2% for venous thromboembolism, and 7.5% for bleeding. Rates of cardiovascular events were similar across platelet counts. Patients with platelet counts <50 × 109 /L had >2-fold higher rates of bleeding than patients with normal platelet counts. These associations were unchanged in time-varying analyses that considered changes in platelet counts during follow-up. Occurrences of cardiovascular and bleeding events were associated with 4-fold to 5-fold increases in 1-year mortality. Conclusions Among patients with cITP, the 1-year risks of cardiovascular events were 1% to 2%, while nearly 8% experienced a bleeding event within 1 year. Cardiovascular events occurred across all platelet levels, while low platelet counts were associated with increased hazards of bleeding. Cardiovascular and bleeding events were strong prognostic factors for mortality.
© 2019 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  bleeding; chronic ITP; epidemiology; mortality; stroke, myocardial infarction; venous thromboembolism

Mesh:

Year:  2019        PMID: 30933417     DOI: 10.1111/jth.14446

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

1.  Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course.

Authors:  R Castelli; G Lambertenghi Delilliers; A Gidaro; M Cicardi; L Bergamaschini
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

Review 2.  Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.

Authors:  Oriana Miltiadous; Ming Hou; James B Bussel
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

3.  A New Tool to Assess the Epidemiology of Immune Thrombocytopenia: The Nordic Country Patient Registry for Romiplostim.

Authors:  Guillaume Moulis
Journal:  EClinicalMedicine       Date:  2019-08-29

Review 4.  Immune Thrombocytopenia (ITP): Current Limitations in Patient Management.

Authors:  Deirdra R Terrell; Cindy E Neunert; Nichola Cooper; Katja M Heitink-Pollé; Caroline Kruse; Paul Imbach; Thomas Kühne; Waleed Ghanima
Journal:  Medicina (Kaunas)       Date:  2020-11-30       Impact factor: 2.430

Review 5.  Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.

Authors:  Galina Tsykunova; Waleed Ghanima
Journal:  Ther Clin Risk Manag       Date:  2022-03-24       Impact factor: 2.423

6.  Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.

Authors:  Shan Chong; Peng Zhao; Rui-Bin Huang; Hu Zhou; Jia-Ning Zhang; Ming Hou; Yi Liu; Hong-Xia Yao; Ting Niu; Jun Peng; Ming Jiang; Yan-Qiu Han; Jian-Da Hu; Ze-Ping Zhou; Lin Qiu; Lian-Sheng Zhang; Xin Wang; Hua-Quan Wang; Ru Feng; Lin-Hua Yang; Liang-Ming Ma; Shun-Qing Wang; Pei-Yan Kong; Wen-Sheng Wang; Hui-Ping Sun; Jing Sun; He-Bing Zhou; Tie-Nan Zhu; Li-Ru Wang; Jing-Yu Zhang; Qiu-Sha Huang; Hai-Xia Fu; Ye-Jun Wu; Yue-Ying Li; Qian-Fei Wang; Qian Jiang; Hao Jiang; Jin Lu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2022-07-26

7.  EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

Authors:  Anna Falanga; Avi Leader; Chiara Ambaglio; Zsuzsa Bagoly; Giancarlo Castaman; Ismail Elalamy; Ramon Lecumberri; Alexander Niessner; Ingrid Pabinger; Sebastian Szmit; Alice Trinchero; Hugo Ten Cate; Bianca Rocca
Journal:  Hemasphere       Date:  2022-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.